Premium
Management of advanced stage intermediate grade non‐Hodgkin's lymphomas
Author(s) -
Liang Raymond H. S.,
Chiu Edmond K. W.,
Chan T. K.,
Todd David,
Loke S. L.
Publication year - 1990
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2900080306
Subject(s) - stage (stratigraphy) , medicine , geology , paleontology
The treatment result of 271 cases of advanced stage intermediate grade lymphoma were reviewed. Ninety‐four patients received CHOP chemotherapy, 45 BACOP and 17 m‐BACOD. The clinical characteristics of the three groups of patients were comparable. Patients receiving CHOP had a complete response (CR) rate of 60 per cent, the disease‐free survival of CR patients was 31 per cent at 5 years. The overall survival following CHOP chemotherapy was 38 per cent at 5 years. The use of the BACOP or m‐BACOD regime did not appear to improve significantly the prognosis of these patients. Clinical staging, B symptoms, age and serum lactate dehydrogenase level were the most important independent prognostic factors.